RM-MET / Metabolic and incretin signalling
Efocipegtrutide
Also known as: HM15211
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Efocipegtrutide is HM15211, a multi-domain investigational construct designed to engage GLP-1, GIP and glucagon receptors. It is not a simple unmodified peptide.
Evidence position
Completed early-phase records and peer-reviewed class coverage support Grade C. The direct public human record is less mature than the phase 2 and phase 3 records for several related candidates.
What the record does not establish
The name alone does not define a matched Fc construct, linker, receptor balance, formulation or verified lot.
Sources
- 01Efocipegtrutide first-in-human studyClinicalTrials.gov
- Shows
- Official HM15211/Efocipegtrutide aliases, phase, design and completion status
- Does not show
- Registration and posted status do not establish efficacy, approval or material quality
- 02Efocipegtrutide definitionNational Cancer Institute
- Shows
- Authoritative identity and triple-receptor mechanism description
- Does not show
- A terminology record is not a clinical result or lot test
- 03Multifunctional incretin peptides in metabolic therapyPubMed
- Shows
- Peer-reviewed class review placing efocipegtrutide among triple agonists
- Does not show
- Review-level context rather than a direct late-stage trial
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBMED / FOUND RECORDS
- Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.Peptides / 2025 MayPMID 40081498 / DOI 10.1016/j.peptides.2025.171380
- A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study.Contemporary clinical trials / 2023 JulPMID 37028504 / DOI 10.1016/j.cct.2023.107176
- Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.World journal of cardiology / 2025 Aug 26PMID 40949933 / DOI 10.4330/wjc.v17.i8.107991
- Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity.Expert opinion on emerging drugs / 2021 SepPMID 34176426 / DOI 10.1080/14728214.2021.1947240
- American Diabetes Association - 77th Scientific Sessions (June 9-13, 2017 - San Diego, California, USA).Drugs of today (Barcelona, Spain : 1998) / 2017 JulPMID 28837185 / DOI 10.1358/dot.2017.53.7.2669148
CLINICALTRIALS.GOV / FOUND RECORDS
- A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)COMPLETED / PHASE1 / Hanmi Pharmaceutical Company LimitedNCT03374241 / DIRECT intervention MATCH: HM15211
- A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLDCOMPLETED / PHASE1 / Hanmi Pharmaceutical Company LimitedNCT03744182 / DIRECT intervention MATCH: HM15211
- Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in SubjectsACTIVE_NOT_RECRUITING / PHASE2 / Hanmi Pharmaceutical Company LimitedNCT04505436 / DIRECT intervention MATCH: Efocipegtrutide